

**IN THE CLAIMS:**

Please amend claim 38 to read as follows. All claims pending, including those unchanged by the present amendment, are reproduced below for the convenience of the Examiner.

- 1                   1.    (Original) A method for delivery of a compound to the surface of, into or  
2 across a biological barrier, the method comprising contacting the barrier with a composition  
3 comprising the compound and a delivery-enhancing transporter,  
4                               wherein the delivery-enhancing transporter comprises sufficient guanidino  
5 or amidino moieties to increase delivery of the compound into or across the barrier compared to  
6 delivery of the compound in the absence of the delivery-enhancing transporter.
- 1                   2.    (Original) The method of claim 1, wherein the delivery-enhancing  
2 transporter comprises a peptide backbone.
- 1                   3.    (Original) The method of claim 1, wherein the delivery-enhancing  
2 transporter comprises a non-peptide backbone.
- 1                   4.    (Original) The method of claim 1, wherein the delivery-enhancing  
2 transporter comprises from 6 to 50 guanidino or amidino moieties.
- 1                   5.    (Original) The method of claim 4, wherein the delivery-enhancing  
2 transporter comprises from 7 to 15 guanidino moieties.
- 1                   6.    (Original) The method of claim 1, wherein the delivery-enhancing  
2 transporter comprises at least 6 contiguous subunits which each include a guanidino or amidino  
3 moiety.

1                   7.    (Original) The method of claim 1, wherein the delivery-enhancing  
2   transporter comprises from 6 to 50 subunits, at least 50% of which include a guanidino or  
3   amidino moiety.

1                   8.    (Original) The method of claim 7, wherein at least about 70% of the  
2   subunits in the delivery-enhancing transporter include a guanidino moiety.

1                   9.    (Original) The method of claim 7, wherein each subunit includes a  
2   guanidino moiety.

1                   10. (Original) The method of claim 7, wherein the subunits are selected from  
2   the group consisting of L-arginine, D-arginine, L-homoarginine and D-homoarginine residues.

1                   11. (Original) The method of claim 10, wherein each subunit is independently a  
2   D- or L-arginine residue.

1                   12. (Original) The method of claim 11, wherein at least one subunit is D-  
2   arginine.

1                   13. (Original) The method of claim 12, wherein all of the arginine residues  
2   have a D-configuration.

1                   14. (Original) The method of claim 1, wherein the compound is a modified  
2   biological agent.

1                   15. (Original) The method of claim 1, wherein the composition comprises at  
2   least two delivery-enhancing transporters.

1                   **16.** (Original) The method of claim 1, wherein the barrier is an intact epithelial  
2 or endothelial tissue layer or layers.

1                   **17.** (Original) The method of claim 1, wherein the compound is a diagnostic  
2 imaging or contrast agent.

1                   **18.** (Original) The method of claim 1, wherein the compound is a non-nucleic  
2 acid.

1                   **19.** (Original) The method of claim 1, wherein the compound is a non-  
2 polypeptide.

1                   **20.** (Original) The method of claim 1, wherein the compound is selected from  
2 the group consisting of antibacterials, antifungals, antivirals, antiproliferatives,  
3 immunosuppressives, vitamins, analgesics, and hormones.

1                   **21.** (Original) The method of claim 1, wherein the biological barrier is skin.

1                   **22.** (Original) The method of claim 21, wherein the compound is delivered into  
2 and across one or more of the stratum corneum, stratum granulosum, stratum lucidum and  
3 stratum germinativum.

1                   **23.** (Original) The method of claim 21, wherein the compound crosses the  
2 stratum corneum in the absence of skin pretreatment.

1                   **24.** (Original) The method of claim 21, wherein the composition is  
2 administered topically and the compound is taken up by cells that comprise the follicular or  
3 interfollicular epidermis.

1                   **25.** (Original) The method of claim **21**, wherein the composition is  
2 administered by a transdermal patch.

1                   **26.** (Original) The method of claim **1**, wherein the compound is a therapeutic  
2 agent for a condition selected from the group consisting of Crohn's disease, ulcerative colitis,  
3 gastrointestinal ulcers, peptic ulcer disease, and abnormal proliferative diseases.

1                   **27.** (Original) The method of claim **26**, wherein the compound is a therapeutic  
2 for ulcers and is selected from the group consisting of an H<sub>2</sub> histamine inhibitor, an inhibitor of  
3 the proton-potassium ATPase, and an antibiotic directed at *Helicobacter pylori*.

1                   **28.** (Original) The method of claim **1**, wherein the compound is a therapeutic  
2 agent for treating a bronchial condition selected from the group consisting of cystic fibrosis,  
3 asthma, allergic rhinitis, and chronic obstructive pulmonary disease.

1                   **29.** (Original) The method of claim **1**, wherein the therapeutic agent is an  
2 antiinflammatory agent selected from the group consisting of a corticosteroid, cromolyn, and  
3 nedocromil.

1                   **30.** (Original) The method of claim **1**, wherein the compound is a therapeutic  
2 agent for treating ischemia, Parkinson's disease, schizophrenia, cancer, acquired immune  
3 deficiency syndrome (AIDS), infections of the central nervous system, epilepsy, multiple  
4 sclerosis, neurodegenerative disease, trauma, depression, Alzheimer's disease, migraine, pain,  
5 and a seizure disorder.

1                   **31.** (Original) The method of claim **1**, wherein the compound is selected from  
2 the group consisting of cyclosporin, insulin, a vasopressin, a leucine enkephalin, calcitonin, 5-  
3 fluorouracil, a salicylamide, a  $\beta$ -lactone, an ampicillin, a penicillin, a cephalosporin, a  $\beta$ -

4 lactamase inhibitor, a quinolone, a tetracycline, a macrolide, a gentamicin, acyclovir, ganciclovir,  
5 a trifluoropyridine, and pentamidine.

1           **32.** (Original) A composition comprising:  
2           an effective amount of a biologically active agent;  
3           a delivery-enhancing transporter having sufficient guanidino or amidino moieties to  
4           increase delivery of the biologically active agent across a biological barrier  
5           compared to the delivery of the biologically active agent in the absence of the  
6           transporter; and  
7           a pharmaceutically acceptable carrier.

1           **33.** (Original) The composition of claim 32, wherein the biologically active  
2           agent is selected from the group consisting of antiviral agents, antibacterial agents, antifungal  
3           agents, antiproliferative agents, immunosuppressive agents, vitamins, analgesic agents and  
4           hormones.

1           **34.** (Original) The composition of claim 33, wherein the biologically active  
2           agent is an antiviral agent selected from the group consisting of acyclovir, famciclovir,  
3           ganciclovir, foscarnet, idoxuridine, sorivudine, trifluridine, valacyclovir, cidofovir, didanosine,  
4           stavudine, zalcitabine, zidovudine, ribavirin and rimantadine.

1           **35.** (Original) The composition of claim 32, wherein the biologically active  
2           agent is an antibacterial agent selected from the group consisting of nafcillin, oxacillin,  
3           penicillin, amoxicillin, ampicillin, cefotaxime, ceftriaxone, rifampin, minocycline, ciprofloxacin,  
4           norfloxacin, erythromycin and vancomycin.

1           **36.** (Original) The composition of claim 32, wherein the biologically active  
2           agent is an antifungal agent selected from the group consisting of amphotericin, itraconazole,

3 ketoconazole, miconazole, nystatin, clotrimazole, fluconazole, ciclopirox, econazole, naftifine,  
4 terbinafine and griseofulvin.

1               **37.** (Original) The composition of claim **32**, wherein the biologically active  
2 agent is an antineoplastic agent selected from the group consisting of pentostatin, 6-  
3 mercaptopurine, 6-thioguanine, methotrexate, bleomycins, etoposide, teniposide, dactinomycin,  
4 daunorubicin, doxorubicin, mitoxantrone, hydroxyurea, 5-fluorouracil, cytarabine, fludarabine,  
5 mitomycin, cisplatin, procarbazine, dacarbazine, paclitaxel, colchicine, and the vinca alkaloids.

1               **38.** (Currently amended) The composition of claim **32**, wherein the biologically  
2 active agent is an immunosuppressive agent selected from the group consisting of methotrexate,  
3 azathioprine, fluorouracil, hydroxyurea, 6-thioguanine, chlorthalidone, mechlorethamine  
4 hydrochloride, carmustine, cyclosporine, taxol or a phosphate-cleavable taxol conjugate,  
5 tacrolimus, vinblastine, dapsone and sulfasalazine.;

1               **39.** (Original) The composition of claim **32**, wherein the biologically active  
2 agent is an analgesic agent selected from the group consisting of lidocaine, bupivacaine,  
3 novocaine, procaine, tetracaine, benzocaine, cocaine, mepivacaine, etidocaine, proparacaine  
4 ropivacaine and prilocaine.

1               **40.** (Original) The composition of claim **33**, wherein the delivery enhancing  
2 transporter is a peptide having from about 6 to about 15 amino acids residues wherein from 6 to  
3 about 12 residues are selected from the group consisting of L-arginine, D-arginine, L-  
4 homoarginine and D-homoarginine.